1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
2Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea
3Department of Medicine, Seoul National University College of Medicine, Seoul, Korea
4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Copyright © 2016 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Author | Phase | Study location | Primary outcome | Characteristics of treatment in each arm | Median follow-up period (mo) | Arm | No. of patients | Oropharyngeal cancer (%) |
---|---|---|---|---|---|---|---|---|
Haddad et al. (2013) [10] | III | United States | OS | CRT with cisplatin | 49 | CRT | 75 | 55.0 |
TPF×3→CRT with docetaxel or carboplatin | TPF/CRT | 80 | 56.0 | |||||
Cohen et al. (2014) [9] | III | Croatia, France, Russia, Spain, United States | OS | CRT with DFHX | N/A | CRT | 135 | 55.6 |
TPF×2→CRT with DFHX | TPF/CRT | 138 | 61.3 | |||||
Paccagnella et al. (2010) [22] | II | Italy | Radiologic | CRT with cispIatin/5-FU | 42 | CRT | 51 | 51.0 |
CR rate | TPF×3→CRT with cispIatin/5-FU | TPF/CRT | 50 | 54.0 | ||||
Hitt et al. (2014) [11] | III | Spain | PFS | CRT with cispIatin | 24 | CRT | 128 | 42.2 |
TTF | TPF×3→CRT with cispIatin | TPF/CRT | 155 | 42.6 | ||||
Ghi et al. (2014) [13] | III | Italy | OS | CRT with cispIatin | 41 | CRT | 207 | 56.0 |
/5-FU or cetuximab | TPF/CRT | 208 | 57.0 | |||||
TPF×3→CRT with cispatin/5-FU or cetuximab | ||||||||
Takacsi-Nagy et al. (2015) [15] | II | Hungary | Radiologic response rate | CRT with cispIatin | 63 | CRT | 33 | 52.0 |
TPF×2→CRT with cispIatin | TPF/CRT | 30 | 61.0 |
Author | Phase | Study location | Primary outcome | Characteristics of treatment in each arm | Median follow-up period (mo) | Arm | No. of patients | Oropharyngeal cancer (%) |
---|---|---|---|---|---|---|---|---|
Haddad et al. (2013) [10] | III | United States | OS | CRT with cisplatin | 49 | CRT | 75 | 55.0 |
TPF×3→CRT with docetaxel or carboplatin | TPF/CRT | 80 | 56.0 | |||||
Cohen et al. (2014) [9] | III | Croatia, France, Russia, Spain, United States | OS | CRT with DFHX | N/A | CRT | 135 | 55.6 |
TPF×2→CRT with DFHX | TPF/CRT | 138 | 61.3 | |||||
Paccagnella et al. (2010) [22] | II | Italy | Radiologic | CRT with cispIatin/5-FU | 42 | CRT | 51 | 51.0 |
CR rate | TPF×3→CRT with cispIatin/5-FU | TPF/CRT | 50 | 54.0 | ||||
Hitt et al. (2014) [11] | III | Spain | PFS | CRT with cispIatin | 24 | CRT | 128 | 42.2 |
TTF | TPF×3→CRT with cispIatin | TPF/CRT | 155 | 42.6 | ||||
Ghi et al. (2014) [13] | III | Italy | OS | CRT with cispIatin | 41 | CRT | 207 | 56.0 |
/5-FU or cetuximab | TPF/CRT | 208 | 57.0 | |||||
TPF×3→CRT with cispatin/5-FU or cetuximab | ||||||||
Takacsi-Nagy et al. (2015) [15] | II | Hungary | Radiologic response rate | CRT with cispIatin | 63 | CRT | 33 | 52.0 |
TPF×2→CRT with cispIatin | TPF/CRT | 30 | 61.0 |
OS, overall survival; CRT, concurrent chemoradiotherapy; TPF, docetaxel, cisplatin, and 5-fluorouracil; DFHX, docetaxel+ hydroxyurea+fluorouracil; N/A, not available; CR, complete response; 5-FU, 5-fluorouracil; PFS, progression-free survival; TTF, time-to-failure.